IgE immunotherapy: a novel concept with promise for the treatment of cancer
Standard
IgE immunotherapy: a novel concept with promise for the treatment of cancer. / Josephs, Debra H; Spicer, James F; Karagiannis, Panagiotis; Gould, Hannah J; Karagiannis, Sophia N.
In: MABS-AUSTIN, Vol. 6, No. 1, 16.01.2014, p. 54-72.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - IgE immunotherapy: a novel concept with promise for the treatment of cancer
AU - Josephs, Debra H
AU - Spicer, James F
AU - Karagiannis, Panagiotis
AU - Gould, Hannah J
AU - Karagiannis, Sophia N
PY - 2014/1/16
Y1 - 2014/1/16
N2 - The importance of antibodies in activating immune responses against tumors is now better appreciated with the emergence of checkpoint blockade antibodies and with engineered antibody Fc domains featuring enhanced capacity to focus potent effector cells against cancer cells. Antibodies designed with Fc regions of the IgE class can confer natural, potent, long-lived immune surveillance in tissues through tenacious engagement of high-affinity cognate Fc receptors on distinct, often tumor-resident immune effector cells, and through ability to activate these cells under tumor-induced Th2-biased conditions. Here, we review the properties that make IgE a contributor to the allergic response and a critical player in the protection against parasites, which also support IgE as a novel anti-cancer modality. We discuss IgE-based active and passive immunotherapeutic approaches in disparate in vitro and in vivo model systems, collectively suggesting the potential of IgE immunotherapies in oncology. Translation toward clinical application is now in progress.
AB - The importance of antibodies in activating immune responses against tumors is now better appreciated with the emergence of checkpoint blockade antibodies and with engineered antibody Fc domains featuring enhanced capacity to focus potent effector cells against cancer cells. Antibodies designed with Fc regions of the IgE class can confer natural, potent, long-lived immune surveillance in tissues through tenacious engagement of high-affinity cognate Fc receptors on distinct, often tumor-resident immune effector cells, and through ability to activate these cells under tumor-induced Th2-biased conditions. Here, we review the properties that make IgE a contributor to the allergic response and a critical player in the protection against parasites, which also support IgE as a novel anti-cancer modality. We discuss IgE-based active and passive immunotherapeutic approaches in disparate in vitro and in vivo model systems, collectively suggesting the potential of IgE immunotherapies in oncology. Translation toward clinical application is now in progress.
KW - Animals
KW - Antibodies, Neoplasm/immunology
KW - Antineoplastic Agents
KW - Humans
KW - Immunization, Passive
KW - Immunoglobulin E/immunology
KW - Immunologic Surveillance/drug effects
KW - Neoplasms, Experimental/drug therapy
U2 - 10.4161/mabs.27029
DO - 10.4161/mabs.27029
M3 - SCORING: Review article
C2 - 24423620
VL - 6
SP - 54
EP - 72
JO - MABS-AUSTIN
JF - MABS-AUSTIN
SN - 1942-0862
IS - 1
ER -